Sildenafil citrate for female sexual arousal disorder: A future possibility?

Corina Schoen, Gloria Bachmann

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations


Female sexual arousal disorder (FSAD) is a common disorder encountered in clinical practice, with self-reported arousal difficulties reported in up to 26% of American women. Various oral therapies for FSAD have been studied, including sildenafil citrate, a phosphodiesterase inhibitor that is currently used to treat male erectile dysfunction. In vitro studies of sildenafil citrate have demonstrated smooth-muscle relaxation in clitoral tissue, and phosphodiesterase type-5 has been shown to be present in vaginal, clitoral and labial smooth muscle; these findings have led to theories that sildenafil citrate might be successful for treating FSAD. This Review discusses the data from clinical trials that have assessed sildenafil citrate for the treatment of FSAD; the trials show that sildenafil citrate is moderately effective. Sildenafil citrate may also be effective in women with FSAD secondary to multiple sclerosis, diabetes or antidepressant use; however, more trials in these patient populations are required to confirm these findings.

Original languageEnglish (US)
Pages (from-to)216-222
Number of pages7
JournalNature Reviews Urology
Issue number4
StatePublished - Apr 2009

All Science Journal Classification (ASJC) codes

  • Urology


Dive into the research topics of 'Sildenafil citrate for female sexual arousal disorder: A future possibility?'. Together they form a unique fingerprint.

Cite this